|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US6861409||NOVO||Growth hormone secretagogues|| |
(1 year, 1 month ago)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8192719||NOVO||Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds|| |
(4 years from now)
Macrilen is owned by Novo.
Macrilen contains Macimorelin Acetate.
Macrilen has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Macrilen are:
Macrilen was authorised for market use on 20 December, 2017.
Macrilen is available in for solution;oral dosage forms.
Macrilen can be used as a method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin.
The generics of Macrilen are possible to be released after 12 October, 2027.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Orphan Drug Exclusivity (ODE)||Dec 20, 2024|
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic